LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Moderate Buy” from Analysts

LivaNova PLC (NASDAQ:LIVN) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $80.75.

LIVN has been the topic of several analyst reports. Robert W. Baird reduced their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Mizuho raised their price objective on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Barclays lifted their price objective on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Finally, KeyCorp upped their target price on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, June 22nd.

Insider Activity

In related news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director owned 7,228 shares in the company, valued at $547,521. This trade represents a 19.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.35% of the stock is currently owned by company insiders.

Institutional Trading of LivaNova

Several institutional investors and hedge funds have recently bought and sold shares of LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of LivaNova by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after buying an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. increased its position in LivaNova by 4.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after acquiring an additional 36,094 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in LivaNova by 10.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock valued at $6,633,000 after acquiring an additional 15,405 shares during the last quarter. Intech Investment Management LLC lifted its position in LivaNova by 19.6% during the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after acquiring an additional 7,195 shares during the period. Finally, Strs Ohio purchased a new position in shares of LivaNova in the 1st quarter valued at approximately $130,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

LIVN opened at $82.24 on Wednesday. The stock’s 50-day moving average price is $72.87 and its 200 day moving average price is $67.23. LivaNova has a 12-month low of $41.01 and a 12-month high of $83.98. The firm has a market cap of $4.52 billion, a price-to-earnings ratio of 42.18 and a beta of 0.88. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, sell-side analysts expect that LivaNova will post 3.73 earnings per share for the current year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.